OncoMatch/Clinical Trials/NCT06927466
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Is NCT06927466 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies B019 for relapsed or refractory b-cell acute lymphoblastic leukemia.
Treatment: B019 — The purpose of the study is to evaluate the safety and tolerability of B019 in subjects.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 expression
Required: CD22 expression
Demographics
Prior therapy
Cannot have received: CAR-T cell therapy
Has had treatment with any prior CAR-T therapy
Lab requirements
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06927466 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Does this trial require CD22?
Yes, CD22 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 25 years or younger and at least 3 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages